In what should come as no surprise to anyone who knows the effects of smoking on patients with asthma, a new report indicates that the latest strings of indoor smoking bans will have a direct impact on reducing emergency room visits due to asthma attacks. Basically, it proves that not subjecting children with breathing problems to tobacco smog is good for their health.
The study was done by researchers at the University of Chicago Medicine, Tech Times reports, and their findings indicate that the ban on smoking indoors results in the drastic reduction of asthma attacks among children that lead to emergency room visits. Three years after the ban was put in effect, ER visits were reduced by 17 percent.
Christina Ciaccio is an expert in pediatric allergy and along with her team, they looked into the emergency room records of over 20 cities where indoor smoking has been banned. After looking at their records from 2000 until 2014, the researchers noted a definite decrease in overall ER visits prompted by breathing problems among asthmatic patients.
This isn’t really surprising since air pollution of any kind has been a major hazard for the 6.3 million American children with asthma living in the U.S. alone. To be fair, other causes of asthma attacks can include everything from car exhaust, factory smoke, allergens, dust, and the occasional overexertion when the weather is cold.
However, as far as causes that induce attacks indoors go, smoking is cited as one of the leading factors, hence the ban. Then again, the researchers themselves acknowledge that their findings are not entirely foolproof since there are some fluctuations in data, MedicalXpress reports. For now, the results of the study simply show that the legislative action pertaining to the smoking ban has a significant impact on public health.


Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 



